Press Release (ePRNews.com) - IRVINE, Calif. - Feb 25, 2019 - Today, Dante Labs launched its Global Epilepsy Whole Genome Study, which will sequence 1,000 patients diagnosed with epilepsy over the next nine months, further advancing the research and development of gene therapies for epilepsy.
The study was first advocated by Epilepsy Awareness Day at Disneyland (EADDL), which will also lead the selection of epilepsy patients for this project.
“Brad and Candy Levy at the Epilepsy Awareness Day at Disneyland have done an amazing job supporting epilepsy patients and their families across the United States and the world,” said Dante Labs CEO Andrea Riposati. “We are excited to dedicate resources to the study of epilepsy.”
To conduct the study, Dante Labs is calling for patients to register their interest on a special page on Dante Labs website. Upon registration, they must upload proof of diagnosis and will be asked to document their consent. Once approved, patients will receive a unique 100 percent discount code to receive the non-invasive test directly at home.
The test consists of a non-invasive saliva collection kit and provides patients with access to a tailor-made epilepsy panel, a general health and wellness report and a report on reaction to current epilepsy treatments. Sequencing will be performed at 30X coverage. Furthermore, patients will gain first-hand research insights and therapeutic updates throughout the study.
“Research already shows epilepsy to have a vast genetic background, much of which is yet to be explored therapeutically,” Riposati stated. “This study will continue to broaden the identification of epilepsy variants, as well as bridging the gap between WGS and treatment pipelines to ensure curative measures are met for epilepsy patients.” Source :